Non-contrast transcatheter aortic valve implantation for patients with aortic stenosis and chronic kidney disease: a pilot study.
aortic stenosis
renal failure
renal insufficiency
transcatheter aortic valve replacement
zero contrast
Journal
Frontiers in cardiovascular medicine
ISSN: 2297-055X
Titre abrégé: Front Cardiovasc Med
Pays: Switzerland
ID NLM: 101653388
Informations de publication
Date de publication:
2023
2023
Historique:
received:
03
03
2023
accepted:
19
05
2023
medline:
30
6
2023
pubmed:
30
6
2023
entrez:
30
6
2023
Statut:
epublish
Résumé
Acute kidney injury (AKI) is frequently observed after transcatheter aortic valve implantation (TAVI). Of note, it is associated with a threefold increase in all-cause and cardiac death. We propose a new non-contrast strategy for evaluating and performing the TAVI procedure that can be especially valuable for patients with aortic stenosis (AS) and chronic kidney disease (CKD) to prevent AKI. Patients with severe symptomatic AS and CKD stage ≥3a were evaluated for TAVI using four non-contrast imaging modalities for procedural planning: transesophageal echocardiogram (TEE), cardiac magnetic resonance, multidetector computed tomography (MDCT), and aortoiliac CO A total of 25 patients underwent TF-TAVI with the zero-contrast technique. The mean age was 79.9 ± 6.1 years, 72% in NYHA class III/IV, with a mean STS-PROM of 3.0% ± 1.5%, and creatinine clearance of 49 ± 7 ml/min. The self-expandable Evolut R and Pro were implanted in 80% and 20% of patients, respectively. In 36% of the cases, the transcatheter heart valve (THV) chosen was one size larger than the one by contrast MDCT, but none of these cases presented adverse events. Device success and the combined safety endpoint (at 30 days) both achieved 92%. Pacemaker implantation was needed in 17%. This pilot study demonstrated that the zero-contrast technique for procedural planning and THV implantation was feasible and safe and might become the preferable strategy for a significant population of CKD patients undergoing TAVR. Future studies with a larger number of patients are still needed to confirm such interesting findings.
Sections du résumé
Background
UNASSIGNED
Acute kidney injury (AKI) is frequently observed after transcatheter aortic valve implantation (TAVI). Of note, it is associated with a threefold increase in all-cause and cardiac death. We propose a new non-contrast strategy for evaluating and performing the TAVI procedure that can be especially valuable for patients with aortic stenosis (AS) and chronic kidney disease (CKD) to prevent AKI.
Methods
UNASSIGNED
Patients with severe symptomatic AS and CKD stage ≥3a were evaluated for TAVI using four non-contrast imaging modalities for procedural planning: transesophageal echocardiogram (TEE), cardiac magnetic resonance, multidetector computed tomography (MDCT), and aortoiliac CO
Results
UNASSIGNED
A total of 25 patients underwent TF-TAVI with the zero-contrast technique. The mean age was 79.9 ± 6.1 years, 72% in NYHA class III/IV, with a mean STS-PROM of 3.0% ± 1.5%, and creatinine clearance of 49 ± 7 ml/min. The self-expandable Evolut R and Pro were implanted in 80% and 20% of patients, respectively. In 36% of the cases, the transcatheter heart valve (THV) chosen was one size larger than the one by contrast MDCT, but none of these cases presented adverse events. Device success and the combined safety endpoint (at 30 days) both achieved 92%. Pacemaker implantation was needed in 17%.
Conclusion
UNASSIGNED
This pilot study demonstrated that the zero-contrast technique for procedural planning and THV implantation was feasible and safe and might become the preferable strategy for a significant population of CKD patients undergoing TAVR. Future studies with a larger number of patients are still needed to confirm such interesting findings.
Identifiants
pubmed: 37388643
doi: 10.3389/fcvm.2023.1175600
pmc: PMC10305775
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1175600Informations de copyright
© 2023 Freire, Nicz, Ribeiro, Filippini, Accorsi, Liberato, Nomura, Cassar, Vieira, Mathias, Pomerantzeff, Tarasoutchi, Abizaid, Kalil Filho and Brito.
Déclaration de conflit d'intérêts
FB and HR are proctors and consultants for Edwards Lifesciences, Medtronic, and Boston Scientific. AA is a proctor for Boston Scientific. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Expert Rev Cardiovasc Ther. 2015 Mar;13(3):301-16
pubmed: 25592763
Arch Cardiovasc Dis. 2014 Feb;107(2):133-9
pubmed: 24556191
Vasc Specialist Int. 2015 Sep;31(3):67-80
pubmed: 26509137
Rev Esp Cardiol (Engl Ed). 2019 Jan;72(1):21-29
pubmed: 29358043
Catheter Cardiovasc Interv. 2015 Sep;86(3):518-27
pubmed: 25641565
Am J Cardiol. 2015 Nov 1;116(9):1391-8
pubmed: 26342515
N Engl J Med. 2017 Apr 6;376(14):1321-1331
pubmed: 28304219
N Engl J Med. 2019 May 2;380(18):1706-1715
pubmed: 30883053
Int J Nephrol. 2012;2012:483748
pubmed: 23365748
JACC Cardiovasc Interv. 2022 Jan 24;15(2):150-161
pubmed: 35057985
Catheter Cardiovasc Interv. 2015 Apr;85(5):E153-62
pubmed: 25510532
Am J Kidney Dis. 2009 Jun;53(6):961-73
pubmed: 19346042
Cardiorenal Med. 2021;11(4):166-173
pubmed: 34261063
J Am Soc Echocardiogr. 2018 Apr;31(4):405-433
pubmed: 29275985
Am J Cardiol. 2023 Mar 1;190:122-124
pubmed: 36623398
J Thorac Cardiovasc Surg. 2013 Jan;145(1):6-23
pubmed: 23084102